A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients.

BMC Cancer · 2014 · PMC3922603 · PMID 24490800

Europe PMC DOI

hedged sentence

0.2370

closest p · 4.7× alpha

0.2370

boldest claim

The sentences

a slight trendp = 0.237not close (p > 0.1)

The MTHFR C677T polymorphisms did not show a statistically significant influence on survival times in all patients (p = 0.412) nor in any analyzed subgroup (in neoadjuvantly treated patients p = 0.745, in primarily resected patients p = 0.295), although there was a slight trend for shorter survival of patients with the CC genotype (54.1 months median in patients with CC genotype versus 82.7 months in patients with CT and TT genotype, p = 0.237), Table 4 a.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.